Metabolic processinggenes, indoleamine 2,3-dioxygenase 1 (IDO1) and fatty acid synthase(FASN), were also both DEGs in both NSCLC subtypes relative to PBMCsand for which targeting drugs are either approved or in clinical trials.47 This evidence concerns the gene FASN and non-small cell lung carcinoma.